Table 3. Associations between the APOE alleles and AD pathological lesions.

	Outcome
	Braak stage of NFTa		CERAD score of neuritic plaquesb		CAAc
					Mild versus none		Moderate versus mild		Severe versusmoderate
	Log [OR (95%CI)]	P value	Log[OR (95%CI)]	P value	Log[OR (95%CI)]	P value	Log[OR (95%CI)]	P value	Log[OR (95%CI)]	P value
Presence of APOEε2 allele	-0.25 (-0.49, -0.01)	0.04	-0.19 (-0.48, 0.09)	0.178	0.09 (-0.10, 0.28)	0.33	0.09 (-0.10, 0.28)	0.33	0.09 (-0.10, 0.28)	0.33
Presence of APOEε4 allele	-0.08 (-0.18, 0.02)	0.14	0.33 (0.17, 0.48)	<0.001	0.38 (0.19, 0.57)	<0.001	0.20 (0.01, 0.39)	0.038	0.04 (-0.18, 0.26)	0.71
Presence of 1 APOEε4 allele	-0.08 (-0.18, 0.03)	0.15	0.31 (0.15, 0.48)	<0.001	0.44 (0.25, 0.64)	<0.001	0.05 (-0.06, 0.17)	0.36	0.05 (-0.06, 0.17)	0.36
Presence of 2 APOEε4 alleles	-0.08 (-0.24, 0.09)	0.38	0.39 (0.09, 0.69)	<0.001	0.17 (-0.21, 0.56)	0.38	0.43 (0.11, 0.75)	0.008	0.36 (0.08, 0.63)	0.010

Effect estimates represent the logarithm of odd ratios. The logarithm of odd ratios was calculated to facilitate comparisons with the estimates resulting from mediation analysis in table 4.

^aFor Braak stage of NFTs, estimates refer to the following comparisons: VI versus V, V versus III/IV, and III/IV versus 0/I/II.

^bFor CERAD score of neuritic plaques, estimates refer to the following comparisons: frequent versus moderate and moderate versus none/sparse.

^cFor CAA, estimates refer to the comparisons indicated in the table. With each one of the three pathological lesions as dependent variable, the model adjusted for the other two of the three pathological lesions, and all demographic and clinical variables (age of death, sex, education, and symptom duration), using the APOEε3/ε3 group as reference group.

Presence of APOEε2 allele: APOEε2/ε2 + APOEε2/ε3 (but not APOEε2/ε4) versus APOEε3/ε3 (reference); presence of APOEε4 allele: APOEε3/ε4 + APOEε4/ε4 (but not APOEε2/ε4) versus APOEε3/ε3 (reference); CAA = cerebral amyloid angiopathy; NFT = neurofibrillary tangles.